Internal Medicine

Cardio-Oncology

Questions discussed in this category

For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

5 Answers available

What are your management strategies for malignant pericardial effusion with a high risk of spontaneous hemorrhage, particularly in patients requiring anticoagulation for chronic atrial fibrillation?

1 Answer available

What are your top takeaways from ACC 2024?

3 Answers available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

Can CAR T cell therapy be considered for heart transplant recipients with concurrent lymphoproliferative disorders?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015-12-17

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Blood, 2022 Jul 14

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Leukemia, 2021 Apr 27

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.

J Am Coll Cardiol, 2019 Oct 01

Cardiovascular Toxicities Associated With Ibrutinib.

Pediatr Transplant, 2021 Aug

Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy.

Br J Haematol, 2023 May 2

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.

Bone marrow transplantation, 2022 Dec 27

CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.

American heart journal, 2020 Oct 13

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

The New England journal of medicine, 2024 Apr 07

Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.

Circulation, 2016-12-13

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

American heart journal, 2022 May 17

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

The New England journal of medicine, 2024 Apr 06

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Related Topics in Internal Medicine